DPY30

Across TCGA pan-cancer cohorts, DPY30 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated DPY30 data layer compared with 22 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher DPY30 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated DPY30 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, PDAC, and CCRCC are the cancer types where DPY30 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.798	0.444	.004	33	view →
PDAC	OS	Median	III,IV	0.495	0.984	.001	22	view →
CCRCC	DFS	Tertile	All	0.655	0.898	.006	20	view →
LSCC	DFS	Median	II,III,IV	0.877	0.539	.005	20	view →
GBM	OS	Quartile	All	0.610	0.371	.027	4	view →
HNSC	DFS	Tertile	IV	0.581	0.862	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

DPY30–LUAD (OS)

Open the LUAD breakdown →